NASDAQ$NEO
NeoGenomics Inc. · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
NeoGenomics reported strong second-quarter results with significant year-over-year growth across all three divisions and strategic position strengthened through acquisitions.
NeoGenomics reported a 40% increase in consolidated revenue, reaching $122 million in the second quarter of 2021. The company's clinical services revenue grew by 37% to $101 million, while pharma services revenue increased by 55% to $20 million. The company also completed the acquisitions of Trapelo Health and Inivata Limited during the quarter.
- Consolidated revenue increased 40% to $122 million.
- Clinical Services revenue increased 37% to $101 million.
- Pharma Services revenue increased 55% to $20 million.
- Completed acquisitions of Trapelo Health and Inivata Limited.
Headline financials
Revenue & EPS history
NeoGenomics · Revenue · Quarterly
$122M
Forward guidance
The Company reiterated its full-year 2021 guidance, initially issued on May 5, 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+2.1%
Avg return
Earnings day
+3.4%
Avg return
5 days after
+2.7%
Avg return
30 days after
53%
34 / 64 earnings
Positive
+28.1%
Q3 2013
Best reaction
-34.0%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.8% | +9.6% | +18.4% | |
| Q4 2025 | +0.5% | -13.1% | -28.1% | |
| Q3 2025 | -2.5% | -3.8% | +19.4% | |
| Q1 2025 | -34.0% | -22.8% | -26.1% | |
| Q4 2024 | -13.9% | -23.0% | -31.1% | |
| Q3 2024 | +9.3% | +11.5% | +21.6% | |
| Q2 2024 | +16.1% | +15.4% | +9.7% | |
| Q1 2024 | -8.3% | +0.5% | -8.0% | |
| Q4 2023 | +14.8% | +16.9% | +7.5% | |
| Q3 2023 | +9.6% | +3.2% | +19.1% | |
| Q2 2023 | -6.2% | -11.0% | -11.3% | |
| Q1 2023 | +19.2% | +26.4% | +13.9% | |
| Q4 2022 | +18.2% | +26.2% | +26.4% | |
| Q3 2022 | +23.1% | +58.5% | +70.0% | |
| Q2 2022 | +16.1% | +23.4% | +3.6% | |
| Q1 2022 | -10.1% | -10.1% | -18.1% | |
| Q4 2021 | +11.2% | +14.4% | -6.0% | |
| Q3 2021 | -11.1% | -6.7% | -34.5% | |
| Q2 2021 | -4.6% | -12.7% | +7.7% | |
| Q1 2021 | -11.6% | -19.5% | -14.0% | |
| Q4 2020 | -4.0% | +0.3% | -12.5% | |
| Q3 2020 | -5.0% | -6.5% | +9.0% | |
| Q2 2020 | +1.9% | +3.8% | +2.4% | |
| Q1 2020 | +2.4% | -14.1% | -8.7% | |
| Q4 2019 | -5.5% | -0.2% | -14.3% | |
| Q3 2019 | +11.3% | +8.7% | +23.7% | |
| Q2 2019 | +0.3% | +4.6% | +2.0% | |
| Q1 2019 | +2.9% | +11.3% | +2.4% | |
| Q4 2018 | +4.6% | +7.6% | +12.5% | |
| Q3 2018 | +15.0% | +12.1% | +3.7% | |
| Q2 2018 | -1.6% | -1.5% | -1.9% | |
| Q1 2018 | +5.2% | +7.0% | +21.1% | |
| Q4 2017 | +12.1% | +15.8% | +9.9% | |
| Q3 2017 | +4.2% | +3.2% | +12.2% | |
| Q2 2017 | +2.5% | +2.5% | +3.5% | |
| Q1 2017 | -11.6% | -12.2% | -13.3% | |
| Q4 2016 | +1.6% | +3.4% | -3.2% | |
| Q3 2016 | +11.6% | +10.1% | +29.4% | |
| Q2 2016 | -1.5% | -5.7% | -14.4% | |
| Q1 2016 | +5.8% | — | — | |
| Q4 2015 | +7.7% | — | — | |
| Q3 2015 | +0.7% | — | — | |
| Q2 2015 | -4.6% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | +0.5% | — | — | |
| Q3 2014 | +6.0% | — | — | |
| Q2 2014 | +24.2% | — | — | |
| Q1 2014 | +8.9% | — | — | |
| Q4 2013 | -10.6% | — | — | |
| Q3 2013 | +28.1% | — | — | |
| Q2 2013 | -3.5% | — | — | |
| Q1 2013 | -1.1% | — | — | |
| Q4 2012 | -10.9% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | -3.5% | — | — | |
| Q1 2011 | -0.6% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.6% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | -3.4% | — | — | |
| Q4 2010 | -3.7% | — | — | |
| Q3 2010 | +9.1% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | -1.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro